Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 11;23(1):162.
doi: 10.1186/s12935-023-02990-y.

Recent advances in non-small cell lung cancer targeted therapy; an update review

Mahmood Araghi  1 , Reza Mannani  2 , Ali Heidarnejad Maleki  3 , Adel Hamidi  4 , Samaneh Rostami  3 , Salar Hozhabri Safa  3 , Fatemeh Faramarzi  5 , Sahar Khorasani  6 , Mina Alimohammadi  7 , Safa Tahmasebi  8 , Reza Akhavan-Sigari  9   10
Affiliations
Review

Recent advances in non-small cell lung cancer targeted therapy; an update review

Mahmood Araghi et al. Cancer Cell Int. .

Abstract

Lung cancer continues to be the leading cause of cancer-related death worldwide. In the last decade, significant advancements in the diagnosis and treatment of lung cancer, particularly NSCLC, have been achieved with the help of molecular translational research. Among the hopeful breakthroughs in therapeutic approaches, advances in targeted therapy have brought the most successful outcomes in NSCLC treatment. In targeted therapy, antagonists target the specific genes, proteins, or the microenvironment of tumors supporting cancer growth and survival. Indeed, cancer can be managed by blocking the target genes related to tumor cell progression without causing noticeable damage to normal cells. Currently, efforts have been focused on improving the targeted therapy aspects regarding the encouraging outcomes in cancer treatment and the quality of life of patients. Treatment with targeted therapy for NSCLC is changing rapidly due to the pace of scientific research. Accordingly, this updated study aimed to discuss the tumor target antigens comprehensively and targeted therapy-related agents in NSCLC. The current study also summarized the available clinical trial studies for NSCLC patients.

Keywords: Immunotherapy; NSCLC; Target antigens; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Target genes and drugs in NSCLC. Various targeted therapy drugs have been summarized that target different key related genes and their signaling pathways in NSCLC
See this image and copyright information in PMC

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. 2018;68(6):394–424. - PubMed
    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA. 2020;70(1):7–30. - PubMed
    1. Blumenschein G, Jr, Kabbinavar F, Menon H, Mok T, Stephenson J, Beck J, et al. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol. 2011;22(9):2057–2067. doi: 10.1093/annonc/mdq731. - DOI - PubMed
    1. García-Campelo R, Bernabé R, Cobo M, Corral J, Coves J, Dómine M, et al. SEOM clinical guidelines for the treatment of non-small cell lung cancer (NSCLC) 2015. Clin Transl Oncol. 2015;17(12):1020–1029. doi: 10.1007/s12094-015-1455-z. - DOI - PMC - PubMed
    1. Majeed U, Manochakian R, Zhao Y, Lou Y. Targeted therapy in advanced non-small cell lung cancer: current advances and future trends. J Hematol Oncol. 2021;14(1):1–20. doi: 10.1186/s13045-021-01121-2. - DOI - PMC - PubMed

LinkOut - more resources